TargetBeta
IL15RA
interleukin 15 receptor subunit alpha · also CD215, IL-15RA · CD molecules
2 programs in company-led studies act on IL15RA, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| nogapendekin alfa inbakiceptrule | ImmunityBio | phase 3 | 4512 running | IL15, IL2RB, IL2RG | ChEMBL |
| SPGL008rule | 3SBio | phase 2 | 33 running | IL15 | the studies' text |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Non-Muscle Invasive Bladder Neoplasms, 2 programs
- Carcinoma, Transitional Cell, 1 program
- Pancreatic Neoplasms, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026nogapendekin alfa inbakicept · ImmunityBio · phase 3 · NCT06829823
- Nov 2027SPGL008 · 3SBio · phase 2 · NCT07874984
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.